Follicular lymphoma with EZH2 mutation

Follicular lymphoma with an EZH2 mutation is a molecularly defined subset of follicular lymphoma, an indolent B-cell non-Hodgkin lymphoma of the lymphatic system characterized by painless lymphadenopathy and germinal center B-cell expansion This clinical entity is defined by somatic gain-of-function mutations in the enhancer of zeste homolog 2 (*EZH2*) gene, an enzymatic component of the polycomb repressive complex 2 (PRC2)

Follicular lymphoma with an EZH2 mutation is a molecularly defined subset of follicular lymphoma, an indolent B-cell non-Hodgkin lymphoma of the lymphatic system characterized by painless lymphadenopathy and germinal center B-cell expansion

This clinical entity is defined by somatic gain-of-function mutations in the enhancer of zeste homolog 2 (*EZH2*) gene, an enzymatic component of the polycomb repressive complex 2 (PRC2) These alterations lead to hypermethylation of histone H3 lysine 27 (H3K27me3), aberrantly silencing tumor suppressor and B-cell differentiation genes to sustain malignant proliferation and lock tumor cells in a germinal center phenotype

This clinical entity is defined by somatic gain-of-function mutations in the enhancer of zeste homolog 2 (*EZH2*) gene, an enzymatic component of the polycomb repressive complex 2 (PRC2) These alterations lead to hypermethylation of histone H3 lysine 27 (H3K27me3), aberrantly silencing tumor suppressor and B-cell differentiation genes to sustain malignant proliferation and lock tumor cells in a germinal center phenotype In oncology practice, identifying this specific biomarker serves as an indic...

These alterations lead to hypermethylation of histone H3 lysine 27 (H3K27me3), aberrantly silencing tumor suppressor and B-cell differentiation genes to sustain malignant proliferation and lock tumor cells in a germinal center phenotype

In oncology practice, identifying this specific biomarker serves as an indication to select targeted epigenetic therapy in adults with relapsed or refractory disease

In oncology practice, identifying this specific biomarker serves as an indication to select targeted epigenetic therapy in adults with relapsed or refractory disease